Convelo Therapeutics, Inc.
Remyelination-enhancing therapies for multiple sclerosis targeting central nervous system repair
- Sector
- Biotech
- Headquarters
- CLEVELAND, OH
- Founded
- 2016
- Latest Form D
- $10.8M, Dec 2022
- Total capital
- $12.8M
- Federal grants
- None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
- Private capital raised
- $12.8M
- 2 Form D · last Dec 2022
- 47 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 20 pending
Capital timeline
Latest events
- Private capital raisedForm D · SEC · 2nd filing$10.8M
- Private capital raisedForm D · SEC · 1st filing$2M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Founders and team
From SEC Form D filings- Bill SanfordDirectorNamed in SEC Form D filings
- Derrick RossiDirectorNamed in SEC Form D filings
- Drew AdamsDirectorNamed in SEC Form D filings
- Paul TesarDirectorNamed in SEC Form D filings
- Ronald RichardDirectorNamed in SEC Form D filings
- Steven LandauExecutive OfficerNamed in SEC Form D filings
What it has protected
USPTO · 0 granted of 20- PendingHydantoin Modulators Of Cholesterol Biosynthesis And Their Use For Promoting RemyelinationUSPTOApplication 19093089
- PendingAzole Modulators Of Cholesterol Biosynthesis And Their Use For Promoting RemyelinationUSPTOApplication 19093086
- PendingSpirocyclic Modulators Of Cholesterol Biosynthesis And Their Use For Promoting RemyelinationUSPTOApplication 18670520
Show all 20 patent records
- Hydantoin Modulators Of Cholesterol Biosynthesis And Their Use For Promoting RemyelinationJan 8, 2026 · Application 19093089Pending
- Azole Modulators Of Cholesterol Biosynthesis And Their Use For Promoting RemyelinationJan 8, 2026 · Application 19093086Pending
- Spirocyclic Modulators Of Cholesterol Biosynthesis And Their Use For Promoting RemyelinationDec 5, 2024 · Application 18670520Pending
- Spirocyclic Cyclic Modulators Of Cholesterol Biosynthesis And Their Use For Promoting RemyelinationDec 5, 2024 · Application 18670608Pending
- Spirocyclic Bicyclic Modulators Of Cholesterol Biosynthesis And Their Use For Promoting RemyelinationNov 28, 2024 · Application 18670537Pending
- Crystalline Forms Of Multicyclic Compounds And Uses ThereofJan 27, 2022 · Application 17299463Pending
- Azole Modulators Of Cholesterol Biosynthesis And Their Use For Promoting RemyelinationApplication 63377821Pending
- Hydantoin Modulators Of Cholesterol Biosynthesis And Their Use For Promoting RemyelinationApplication 63377914Pending
- Spirocyclic Cyclic Modulators Of Cholesterol Biosynthesis And Their Use For Promoting RemyelinationApplication 63282354Pending
- Spirocyclic Bicyclic Modulators Of Cholesterol Biosynthesis And Their Use For Promoting RemyelinationApplication 63282357Pending
- Spirocyclic Modulators Of Cholesterol Biosynthesis And Their Use For Promoting RemyelinationApplication 63282362Pending
- Crystalline Forms Of Multicyclic Compounds And Uses ThereofApplication PCTUS2019063963Pending
- Compounds And Methods Of Promoting MyelinationApplication PCTUS2018067302Pending
- Crystalline Forms of Multicyclic Compounds and Uses ThereofApplication 62774636Pending
- Compounds And Methods Of Promoting MyelinationApplication 62609908Pending
- Spirocyclic Compounds For Use In Promoting RemyelinationApplication PCTUS2025056342Pending
- CYP51 Inhibitors And Method Of Using SameApplication PCTUS2025036825Pending
- Spirocyclic Compounds For Use In Promoting RemyelinationApplication 63722964Pending
- CYP51 Inhibitors And Method Of Using SameApplication 63668541Pending
- Tertiary Pyridyl Amine Modulators Of Cholesterol Biosynthesis And Their Use For Promoting RemylinationApplication 63579221Pending
Related companies, and why
- ImmunoCellular Therapeutics, Ltd.Similar federal contract value in Biotech · null in contracts
- Morphoceuticals, Inc.Similar federal contract value in Biotech · null in contracts
- Genprex, Inc.Similar federal contract value in Biotech · null in contracts
- Octagon Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- nferenceSimilar federal contract value in Biotech · null in contracts
- HDL THERAPEUTICS, INC.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .